Therefore, for the treatment of psoriasis, especially for the more serious forms, in recent decades, there has been a great development of biological drugs based on the use of antibodies against cytokines, particularly against TNF-α, IL-17A, IL-17F, and IL-23, which are not only involved in skin lesions, but they can also have systemic effects [18,35,36,37]. The gene discussed is IL17A; the disease is psoriasis.